<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312195</url>
  </required_header>
  <id_info>
    <org_study_id>BUP3201</org_study_id>
    <nct_id>NCT00312195</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain</brief_title>
  <official_title>An Open-label Run-in, Followed by a Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Show the Effectiveness of Buprenorphine Transdermal System in Management of Patients With Chronic Nonmalignant Pain Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Napp Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate the effectiveness and tolerability of the
      buprenorphine transdermal system (5, 10 and 20) in comparison to matching placebo transdermal
      system in subjects with chronic nonmalignant pain syndromes currently controlled by oral
      opioids. The double-blind treatment intervention duration is 2 weeks during which time
      supplemental analgesic medication (acetaminophen) will be provided to all subjects in
      addition to study drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical
      experience indicating it to be safe and effective in a variety of therapeutic situations for
      the relief of moderate to severe pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">July 2001</completion_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Subjects With Ineffective Treatment During the Double-blind Evaluation Phase.</measure>
    <time_frame>Double-blind phase (14 days)</time_frame>
    <description>Ineffective treatment was defined as:
Subject took &gt;1 gram of acetaminophen in a 24-hour period, or
Subject required a change in transdermal patch (TDS) dose, or
Subject had difficulty in keeping the TDS on, or
Subject discontinued due to ineffective treatment (but did not meet any of the above criteria).
Note: some subjects may have had multiple reasons for ineffective treatment and are counted under each category. Therefore the sum of subjects across all criteria for ineffective treatment is greater than the total number of subjects with ineffective treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time (Days) From the Initial Dose of Study Drug in the Double-blind Evaluation Phase to Ineffective Treatment</measure>
    <time_frame>14 days</time_frame>
    <description>The time of ineffective treatment was calculated as the earliest of the following:
The date the subject first took &gt;1 gram of acetaminophen,
The visit date when ineffective treatment was first determined, or
The date the last patch was removed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Who Had Ineffective Treatment or Who Discontinued Due to Reasons Other Than Ineffective Treatment in the Double-blind Phase</measure>
    <time_frame>14 days</time_frame>
    <description>Note: The total numbers of &quot;Subjects w/ineffective treatment or who discont'd&quot; for placebo and BTDS are 1 less because there were reasons other than lack of efficacy that made up this total: adverse event, death, lost to follow- up, protocol violation, and other. Example for placebo 89+5=94; however, 93 is indicated for the total because there is 1 subject in the placebo group who was counted under ineffective treatment and discontinued due to reasons other than lack of efficacy. The same is true for 1 subject in BTDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Amount of Rescue Medication Used for Pain (Average Daily Number of Acetaminophen Tablets).</measure>
    <time_frame>14 days</time_frame>
    <description>The average daily acetaminophen (Panadol) use (1 tablet = 500 mg) during the double-blind phase was compared between the treatment groups using ANCOVA methodology with terms for country and treatment. The average escape medication used in the last 4 days prior to randomization was included as a covariate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Chronic Non-malignant Pain</condition>
  <arm_group>
    <arm_group_label>BTDS (5, 10 or 20)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine transdermal patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match BTDS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match buprenorphine transdermal patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine transdermal patch</intervention_name>
    <description>Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.</description>
    <arm_group_label>BTDS (5, 10 or 20)</arm_group_label>
    <other_name>Butransâ„¢</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match BTDS</intervention_name>
    <description>Placebo to match buprenorphine transdermal patch applied for 7-day wear.</description>
    <arm_group_label>Placebo to match BTDS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 2 month's history of nonmalignant pain, currently in stable pain control on
             opioid therapy.

          -  Good, very good or excellent pain control on current opioid therapy.

          -  Willing and able to use a telephone interactive voice response service.

        Exclusion Criteria:

          -  Currently receiving daily morphine or oxycodone monotherapy.

          -  Scheduled for surgery of the disease site (eg, major joint replacement surgery), or
             any other major surgery, which would fall within the study period.

        Other protocol-specific exclusion/inclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hawthorne and York</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center Inc</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consultants Inc</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research Inc</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research Deland</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research Inc,</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Research LLC</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Research LLC</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medicine Associates</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain Management and Rehabilitation</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Center for Headache and Pain</name>
      <address>
        <city>Crestview Heights</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Family Medical Center PC</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Clinic</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornerstone Research Care</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALL-TRIALS Clinical Research LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Chardon</city>
        <state>Ohio</state>
        <zip>44024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Solutions</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Management</name>
      <address>
        <city>New Berlin</city>
        <state>Wisconsin</state>
        <zip>53151</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whiteabbey Health Centre</name>
      <address>
        <city>Newtownabbey</city>
        <state>Belfast</state>
        <zip>BT37 9QN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antrim Coast Fundholding Group</name>
      <address>
        <city>Lame</city>
        <state>Co Antrim</state>
        <zip>BT40 1XH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portglenone Health Centre</name>
      <address>
        <city>Portglenone</city>
        <state>CO Antrim</state>
        <zip>BT44 8AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Garden Street Surgery</name>
      <address>
        <city>Magherafelt</city>
        <state>Co Derry</state>
        <zip>BT45 5DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springhill Surgery</name>
      <address>
        <city>Bangor</city>
        <state>Co Down</state>
        <zip>BT19 1PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bennett Road Surgery</name>
      <address>
        <city>Keresley End</city>
        <state>Coventry</state>
        <zip>CV7 8LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Common Surgery</name>
      <address>
        <city>Bexhill-on-Sea</city>
        <state>E Sussex</state>
        <zip>TN39 4SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Old Town Surgery</name>
      <address>
        <city>Bexhill-on-Sea</city>
        <state>E Sussex</state>
        <zip>TN40 2HG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roebuck House Surgery</name>
      <address>
        <city>Hastings</city>
        <state>E Sussex</state>
        <zip>TN34 3EY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leslie Surgery</name>
      <address>
        <city>Glenrothes</city>
        <state>Fife</state>
        <zip>KY6 3LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valleyfield Health Centre</name>
      <address>
        <city>High Valleyfield</city>
        <state>Fife</state>
        <zip>KY12 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashvale Health Centre</name>
      <address>
        <city>Aldershot</city>
        <state>Hants</state>
        <zip>GU12 5BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Academy Medical Practice</name>
      <address>
        <city>Coatbridge</city>
        <state>Lanarkshire</state>
        <zip>L5 3AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanbury Health Centre Group Practice</name>
      <address>
        <city>Sunbury-on-Thames</city>
        <state>Middx</state>
        <zip>TW16 6RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Surgery</name>
      <address>
        <city>Houston</city>
        <state>Renfrewshire</state>
        <zip>PA6 7AR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Burns Practice</name>
      <address>
        <city>Doncaster</city>
        <state>S Yorkshire</state>
        <zip>DN1 2EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grosvenor Medical Centre</name>
      <address>
        <city>Tunbridge Wells</city>
        <state>W Sussex</state>
        <zip>TN1 2EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gables Medical Section</name>
      <address>
        <city>Coventry</city>
        <state>Warwickshire</state>
        <zip>CV6 4DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ridge Medical Practice, Great Horton</name>
      <address>
        <city>Bradford</city>
        <state>West Yorkshire</state>
        <zip>BD7 3EE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townhead Health Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G31 2ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castlemilk Health Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G45 9AW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://app.purduepharma.com/xmlpublishing/pi.aspx?id=b</url>
    <description>Product Information</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2006</study_first_submitted>
  <study_first_submitted_qc>April 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2006</study_first_posted>
  <results_first_submitted>July 29, 2010</results_first_submitted>
  <results_first_submitted_qc>September 28, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 15, 2010</results_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic pain</keyword>
  <keyword>opioid</keyword>
  <keyword>transdermal</keyword>
  <keyword>Butransâ„¢ [BTDS]</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>(First patient first visit) 19-Mar-2001 to (last patient last visit) 22-Jul-2001 at 42 centers: 21 in the UK and 21 in the US.</recruitment_details>
      <pre_assignment_details>The Run-in period (N = 588 subjects started) consisted of titration from buprenorphine transdermal patch (BTDS) 5 to BTDS 10, or 20 mcg/h for tolerability. If BTDS was not tolerated or pain increased, the subject was discontinued. N = 267 subjects were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Double-blind Placebo Patch</title>
          <description>Reference drug - Placebo transdermal patch to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.</description>
        </group>
        <group group_id="P2">
          <title>Double-blind BTDS</title>
          <description>Test drug - buprenorphine transdermal patch (BTDS) 5, 10, or 20 mcg/h applied for 7-day wear.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Double-blind Placebo Patch</title>
          <description>Reference drug - Placebo transdermal patch to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.</description>
        </group>
        <group group_id="B2">
          <title>Double-blind BTDS</title>
          <description>Test drug - buprenorphine transdermal patch (BTDS) 5, 10, or 20 mcg/h applied for 7-day wear.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="138"/>
            <count group_id="B2" value="129"/>
            <count group_id="B3" value="267"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="11.48"/>
                    <measurement group_id="B2" value="56.2" spread="13.34"/>
                    <measurement group_id="B3" value="57.7" spread="12.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects With Ineffective Treatment During the Double-blind Evaluation Phase.</title>
        <description>Ineffective treatment was defined as:
Subject took &gt;1 gram of acetaminophen in a 24-hour period, or
Subject required a change in transdermal patch (TDS) dose, or
Subject had difficulty in keeping the TDS on, or
Subject discontinued due to ineffective treatment (but did not meet any of the above criteria).
Note: some subjects may have had multiple reasons for ineffective treatment and are counted under each category. Therefore the sum of subjects across all criteria for ineffective treatment is greater than the total number of subjects with ineffective treatment.</description>
        <time_frame>Double-blind phase (14 days)</time_frame>
        <population>The Full Analysis Population (N = 266) for efficacy analyses included all subjects who were randomized and provided at least 1 efficacy assessment in the double-blind phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind Placebo Patch</title>
            <description>Reference drug - Placebo transdermal patch to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.</description>
          </group>
          <group group_id="O2">
            <title>Double-blind BTDS</title>
            <description>Test drug - buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Placebo and BTDS combined.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Ineffective Treatment During the Double-blind Evaluation Phase.</title>
          <description>Ineffective treatment was defined as:
Subject took &gt;1 gram of acetaminophen in a 24-hour period, or
Subject required a change in transdermal patch (TDS) dose, or
Subject had difficulty in keeping the TDS on, or
Subject discontinued due to ineffective treatment (but did not meet any of the above criteria).
Note: some subjects may have had multiple reasons for ineffective treatment and are counted under each category. Therefore the sum of subjects across all criteria for ineffective treatment is greater than the total number of subjects with ineffective treatment.</description>
          <population>The Full Analysis Population (N = 266) for efficacy analyses included all subjects who were randomized and provided at least 1 efficacy assessment in the double-blind phase.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects With Ineffective Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason: took more than 1 gram of acetaminophen/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason: required a change in TDS dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason: difficulty keeping patch on</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason: discontinued due to ineffective treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: the odds of ineffective treatment is the same for subjects receiving placebo as for those receiving BTDS versus the alternative H1: the odds of ineffective treatment is different for subjects receiving placebo from those receiving BTDS.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0217</p_value>
            <p_value_desc>P value is from a logistic regression analysis with terms for treatment effect, country and pain site (hip, knee, back and other).</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.2544</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>2.95</ci_upper_limit>
            <estimate_desc>Primary variable was defined as: ratio of the probability of having ineffective treatment divided by the probability of having effective treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time (Days) From the Initial Dose of Study Drug in the Double-blind Evaluation Phase to Ineffective Treatment</title>
        <description>The time of ineffective treatment was calculated as the earliest of the following:
The date the subject first took &gt;1 gram of acetaminophen,
The visit date when ineffective treatment was first determined, or
The date the last patch was removed.</description>
        <time_frame>14 days</time_frame>
        <population>Full Analysis (N = 266) consisted of subjects who were randomized into the double-blind evaluation phase, were exposed to study drug, and provided at least 1 efficacy assessment during the double-blind evaluation phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind Placebo Patch</title>
            <description>Reference drug - Placebo transdermal patch to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.</description>
          </group>
          <group group_id="O2">
            <title>Double-blind BTDS</title>
            <description>Test drug - buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.</description>
          </group>
        </group_list>
        <measure>
          <title>Time (Days) From the Initial Dose of Study Drug in the Double-blind Evaluation Phase to Ineffective Treatment</title>
          <description>The time of ineffective treatment was calculated as the earliest of the following:
The date the subject first took &gt;1 gram of acetaminophen,
The visit date when ineffective treatment was first determined, or
The date the last patch was removed.</description>
          <population>Full Analysis (N = 266) consisted of subjects who were randomized into the double-blind evaluation phase, were exposed to study drug, and provided at least 1 efficacy assessment during the double-blind evaluation phase.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="0.44"/>
                    <measurement group_id="O2" value="7.4" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Who Had Ineffective Treatment or Who Discontinued Due to Reasons Other Than Ineffective Treatment in the Double-blind Phase</title>
        <description>Note: The total numbers of &quot;Subjects w/ineffective treatment or who discont'd&quot; for placebo and BTDS are 1 less because there were reasons other than lack of efficacy that made up this total: adverse event, death, lost to follow- up, protocol violation, and other. Example for placebo 89+5=94; however, 93 is indicated for the total because there is 1 subject in the placebo group who was counted under ineffective treatment and discontinued due to reasons other than lack of efficacy. The same is true for 1 subject in BTDS.</description>
        <time_frame>14 days</time_frame>
        <population>Full Analysis (N = 266) consisted of subjects who were randomized into the double-blind evaluation phase, were exposed to study drug, and provided at least 1 efficacy assessment during the double-blind evaluation phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind Placebo Patch</title>
            <description>Reference drug - Placebo transdermal patch to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.</description>
          </group>
          <group group_id="O2">
            <title>Double-blind BTDS</title>
            <description>Test drug - buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Who Had Ineffective Treatment or Who Discontinued Due to Reasons Other Than Ineffective Treatment in the Double-blind Phase</title>
          <description>Note: The total numbers of &quot;Subjects w/ineffective treatment or who discont'd&quot; for placebo and BTDS are 1 less because there were reasons other than lack of efficacy that made up this total: adverse event, death, lost to follow- up, protocol violation, and other. Example for placebo 89+5=94; however, 93 is indicated for the total because there is 1 subject in the placebo group who was counted under ineffective treatment and discontinued due to reasons other than lack of efficacy. The same is true for 1 subject in BTDS.</description>
          <population>Full Analysis (N = 266) consisted of subjects who were randomized into the double-blind evaluation phase, were exposed to study drug, and provided at least 1 efficacy assessment during the double-blind evaluation phase.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects w/ineffective treatment or who discont'd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ineffective Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to other reasons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Amount of Rescue Medication Used for Pain (Average Daily Number of Acetaminophen Tablets).</title>
        <description>The average daily acetaminophen (Panadol) use (1 tablet = 500 mg) during the double-blind phase was compared between the treatment groups using ANCOVA methodology with terms for country and treatment. The average escape medication used in the last 4 days prior to randomization was included as a covariate.</description>
        <time_frame>14 days</time_frame>
        <population>Full Analysis (N = 266) consisted of subjects who were randomized into the double-blind evaluation phase, were exposed to study drug, and provided at least 1 efficacy assessment during the double-blind evaluation phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind Placebo Patch</title>
            <description>Reference drug - Placebo transdermal patch to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.</description>
          </group>
          <group group_id="O2">
            <title>Double-blind BTDS</title>
            <description>Test drug - buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.</description>
          </group>
        </group_list>
        <measure>
          <title>The Amount of Rescue Medication Used for Pain (Average Daily Number of Acetaminophen Tablets).</title>
          <description>The average daily acetaminophen (Panadol) use (1 tablet = 500 mg) during the double-blind phase was compared between the treatment groups using ANCOVA methodology with terms for country and treatment. The average escape medication used in the last 4 days prior to randomization was included as a covariate.</description>
          <population>Full Analysis (N = 266) consisted of subjects who were randomized into the double-blind evaluation phase, were exposed to study drug, and provided at least 1 efficacy assessment during the double-blind evaluation phase.</population>
          <units>Tablets</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.15"/>
                    <measurement group_id="O2" value="1.8" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs)that occurred after the signing of the informed consent up to end of study, discontinuation, or Serious AE occurring up to 30 days following the last study visit were followed until the AE resolved.</time_frame>
      <desc>Adverse Events were learned of through spontaneous reports and subject interview.</desc>
      <group_list>
        <group group_id="E1">
          <title>Double-blind Placebo Patch</title>
          <description>Reference drug - Placebo transdermal patch to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.</description>
        </group>
        <group group_id="E2">
          <title>Double-blind BTDS</title>
          <description>Test drug - buprenorphine transdermal patch (BTDS) 5, 10, or 20 mcg/h applied for 7-day wear.</description>
        </group>
        <group group_id="E3">
          <title>Open-label Run-in Period BTDS 5, 10 or 20</title>
          <description>Buprenorphine transdermal patch (BTDS) 5, 10, or 20 mcg/h applied for 7-day wear.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART (5.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Fibrillation, atrial</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain abdominal</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Injury accidental</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Pain, chest</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.50</frequency_threshold>
        <default_vocab>COSTART (5.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="245" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Vomit</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema at site</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="588"/>
              </event>
              <event>
                <sub_title>Pruritus at site</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="588"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Leader, Executive Medical Director</name_or_title>
      <organization>Purdue Pharma L.P.</organization>
      <phone>800-733-1333</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

